Artelo Biosciences (ARTL) announced that on May 20, 2025 Artelo’s Board of Directors approved a 6-for-1 reverse stock split of the Company’s common stock. The Company’s common shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market commencing at the market open, June 13, 2025. The Board of Directors determined the 6-for-1 ratio to be appropriate in order to increase the price per share of the Common Stock to meet the continued listing requirement of the Nasdaq Stock Market of a minimum of $1.00 per share closing bid price. The new CUSIP number for the Common Stock following the Reverse Split will be 04301G607.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARTL:
- Artelo Biosciences announces presentation of new data on FABP inhibitors
- Artelo Biosciences announces publication of paper on FABP inhibitor program
- Artelo Biosciences Reports Q1 2025 Financial Results
- Artelo Biosciences Faces Nasdaq Compliance Challenge
- Artelo Biosciences reports Q1 EPS (72c) vs (78c) last year